Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
2005 1
2006 1
2008 1
2009 1
2010 7
2011 6
2012 8
2013 5
2014 4
2016 5
2017 2
2018 5
2019 7
2020 4
2021 7
2022 14
2023 9
2024 6
2025 10

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW, Coppock G, Diva U, Gesualdo L, Heerspink HJL, Inrig JK, Kirsztajn GM, Kohan D, Komers R, Kooienga LA, Lieberman K, Mercer A, Noronha IL, Perkovic V, Radhakrishnan J, Rote W, Rovin B, Tesar V, Trimarchi H, Tumlin J, Wong MG, Trachtman H; DUPRO Steering Committee and DUPLEX Investigators. Rheault MN, et al. N Engl J Med. 2023 Dec 28;389(26):2436-2445. doi: 10.1056/NEJMoa2308550. Epub 2023 Nov 3. N Engl J Med. 2023. PMID: 37921461 Clinical Trial.
MST3 is involved in ENaC-mediated hypertension.
Lu TJ, Kan WC, Yang SS, Jiang ST, Wu SN, Ling P, Bao BY, Lin CY, Yang ZY, Weng YP, Chan CH, Lu TL. Lu TJ, et al. Among authors: kan wc. Am J Physiol Renal Physiol. 2019 Jul 1;317(7):F30-F42. doi: 10.1152/ajprenal.00455.2018. Epub 2019 Apr 10. Am J Physiol Renal Physiol. 2019. PMID: 30969802 Free article.
Non-Inferiority of Subcutaneous Efepoetin Alfa Compared to Methoxy Polyethylene Glycol-Epoetin Beta in Stage 3 or 4 CKD Patients: Insights From a Phase 3 Trial.
Roger SD, Wong CM, Vejakama P, Rahardjo KD, Hsu BG, Lee CM, Wu IW, Lee CC, Situmorang TD, Krisanapan P, Mazlan SA, Peng YS, Sarwono J, De Asis N, Solimen D, Jonny, Sangthawan P, Chen JB, Wang CL, Chung S, Villaflor AJ, Yang CW, Kan WC, Yang Y, Rubio-Bicol J, Yan LY, Lee SH, Chiu YW, Chen CH, Na KY, Hassah WHHW, Kang YS, Choi BS, Aquitania G, Na KR, Wu MS, Ahmad MK, Isidto R, Wu V, Leong GB, Sung JM, Noppakun K, Chou KJ, Abdul Wahab MZ, Shin SJ, Nugroho P. Roger SD, et al. Among authors: kan wc. Nephrology (Carlton). 2025 May;30(5):e70046. doi: 10.1111/nep.70046. Nephrology (Carlton). 2025. PMID: 40369895 Free PMC article. Clinical Trial.
93 results